Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K9BV
|
|||
| Former ID |
DIB004744
|
|||
| Drug Name |
TVB-2640
|
|||
| Indication | Astrocytoma [ICD-11: 2A00.0Y] | Phase 2 | [1], [2] | |
| Colon cancer [ICD-11: 2B90.Z] | Phase 2 | [1] | ||
| Advanced solid tumour [ICD-11: 2A00-2F9Z; ICD-9: 140-199] | Phase 1 | [3] | ||
| Company |
3-v biosciences
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT02223247) A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors. U.S. National Institutes of Health. | |||
| REF 4 | Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. ACS Med Chem Lett. 2013 January 10; 4(1): 113-117. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.